R R Henry
Overview
Explore the profile of R R Henry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cariou B, Leiter L, Muller-Wieland D, Bigot G, Colhoun H, Del Prato S, et al.
Diabetes Metab
. 2017 Mar;
43(5):453-459.
PMID: 28347654
Aims: The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study. Described here is the rationale behind a phase-IIIb study...
2.
Mudaliar S, Henry R, Ciaraldi T, Armstrong D, Burke P, Pettus J, et al.
Diabetes Obes Metab
. 2016 Oct;
18 Suppl 2:17-24.
PMID: 27723226
Aims: Basal insulin peglispro (BIL), a novel PEGylated basal insulin with a large hydrodynamic size, has a delayed absorption and reduced clearance that prolongs the duration of action. The current...
3.
Inzucchi S, Nauck M, Hehnke U, Woerle H, von Eynatten M, Henry R
Diabetes Obes Metab
. 2015 May;
17(9):868-77.
PMID: 25974030
Aim: To assess the efficacy, hypoglycaemia risk and other safety markers of linagliptin as an additional therapy in older patients (aged ≥70 years) inadequately controlled with basal insulin. Methods: A...
4.
Henry R, Buse J, Wu H, Durrwell L, Mingrino R, Jaekel K, et al.
Diabetes Obes Metab
. 2015 Mar;
17(6):560-565.
PMID: 25728612
Aims: To evaluate the potential efficacy, safety and tolerability of aleglitazar as monotherapy or add-on therapy to metformin or to a sulphonylurea (either alone or in combination with metformin). Methods:...
5.
Henry R, Staels B, Fonseca V, Chou M, Teng R, Golm G, et al.
Diabetes Obes Metab
. 2013 Aug;
16(3):223-30.
PMID: 23909985
Aim: To evaluate the efficacy and safety of initial combination therapy of sitagliptin 100 mg/day coadministered with all marketed doses of pioglitazone in patients with type 2 diabetes. Methods: Patients...
6.
Bray G, Smith S, Banerji M, Tripathy D, Clement S, Buchanan T, et al.
Diabetes Obes Metab
. 2013 Apr;
15(10):931-7.
PMID: 23551856
Aims: This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and...
7.
Mudaliar S, Henry R
Diabetologia
. 2012 May;
55(7):1865-8.
PMID: 22555471
The incretins are gut hormones secreted in response to nutrient/carbohydrate ingestion and act on the pancreatic beta cell to amplify glucose-stimulated insulin secretion. Incretin hormone-based treatments for patients with type...
8.
Henry R, Murray A, Marmolejo M, Hennicken D, Ptaszynska A, List J
Int J Clin Pract
. 2012 Mar;
66(5):446-56.
PMID: 22413962
Background: Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week...
9.
Henry R, Aroda V, Mudaliar S, Garvey W, Chou H, Jones M
Diabetes Obes Metab
. 2011 Aug;
14(1):40-6.
PMID: 21831167
Aim: Colesevelam lowers glucose and low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. This study examined the mechanisms by which colesevelam might affect glucose control. Methods: In...
10.
Henry R, Smith S, Schwartz S, Mudaliar S, Deacon C, Holst J, et al.
Diabetes Obes Metab
. 2011 May;
13(9):850-8.
PMID: 21554520
Aim: To study the effect of dipeptidyl peptidase-4 (DPP-4) inhibition with saxagliptin on β-cell function as reflected by the stimulated insulin secretion rate after an enteral glucose load in patients...